Straight Outta Amsterdam: An ECCMID Recap

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 View more SIDPEC Activities

Activity Description

In this 4-episode podcast miniseries, Ryan Shields and Erin McCreary review key posters, presentations, and other data from the 2019 European Congress of Clinical Microbiology & Infectious Diseases.

Episode 1: How ECCMID 2019 went viral - Panelists review results of ASPECT-NP (Ceftolozane-tazobactam versus meropenem in patients with ventilated nosocomial pneumonia), CAMERA-2 (Combination therapy for methicillin-resistant Staphylococcus aureus bacteraemia), and Exebacase for patients with methicillin-resistant Staphylococcus aureus bacteraemia (Phase 2). Episode 2: Nerding Out at ECCMID 2019 - Panelists share their secret passions and nerdiest moments from ECCMID 2019, including multi-omics data for Pseudomonas aeruginosa, the effects of chemotherapy on antimicrobial resistance, phage therapy, and more!

Episode 3: Tazobactam and Tulips: Hot Topics from ECCMID 2019 - Panelists review expanded MERINO trial data including mortality by pathogen MIC, PK-PD principles, BLING III, beta-lactam therapeutic drug monitoring, linezolid dosing in renal impairment, microbiology issues, and updates from EUCAST. Episode 4: Rapid Fire Data from ECCMID 2019 - Panelists go “rapid fire” through posters and oral abstracts presented at ECCMID 2019, including: rapid diagnostics, the influence of leadership in antimicrobial stewardship, iPad technology and patient’s beliefs about antibiotics, imipenem-relebactam, cefiderocol, rezafungin, ibrexafungerp, sulbactam-ETX2514, iclaprim, lefamulin, and tebipenem.

Learning Objectives

The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:

  • Describe a late-breaking clinical trial presented at the 2019 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
  • Discuss antimicrobial stewardship strategies from institutions around the globe.
  • Determine the role in therapy for new and pipeline antimicrobials.


Erin K. McCreary, PharmD, BCPS, BCIDP
Antimicrobial Stewardship/Infectious Diseases Clinical Pharmacist
University of Pittsburgh Medical Center
Pittsburgh, PA

Ryan K. Shields, PharmD, MS
Associate Professor of Medicine
University of Pittsburgh
Pittsburgh, PA

CE Accreditation

Release Date: 07-10-2019
Expiration Date: 07-10-2022


This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-227-H01-P has been assigned to this home study, knowledge-based activity (initial release date 7-10-2019). This activity is approved for 2.0 contact hour (0.2 CEU) in states that recognize ACPE providers. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.


The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. McCreary has no relevant commercial or financial relationships to disclose. Dr. Shields has served as a speaker and/or consultant for Menarini, Nabriva, Pfizer, Shionogi, and T2Biosystems, and has received research funding from Accelerate Diagnostics, Achaogen, Allergan, Merck, Roche, Shionogi, Tetraphase, and Venatorx.


This activity is provided by ProCE, Inc. and SIDP.


The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.